

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Currently amended): A complex of an amphiphilic copolymer with a water soluble cationic bioactive agent, wherein the amphiphilic copolymer has benzoyl sulfonic acid groups on the hydrophobic segment of said copolymer.
2. (Previously presented): A complex according claim 1, wherein said complex forms micelles in aqueous media.
3. (Original): A complex according to claim 1, wherein the amphiphilic copolymer is comprised of a hydrophilic polymer selected from the group consisting of: a polyalkylether, dextran, dextran, carboxymethyldextran, dextran sulfate, aminodextran, cellulose, carboxymethyl cellulose, chitin, chitosan, succinyl chitosan, carboxymethylchitin, carboxymethylchitosan, hyaluronic acid, a starch, an alginate, chondroitin sulfate, albumin, pullulan, carboxymethyl pullulan, polyglutamic acid, polylysine, polyaspartic acid, HPMA, styrene maleic anhydride copolymer, divinylethyl ether maleic anhydride copolymer, polyvinyl pyrrolidone, and polyvinylalcohol.
4. (Previously presented): A complex according to claim 1, wherein the amphiphilic polymer is a block copolymer made of hydrophilic and hydrophobic polymers.
5. (Original): A complex according to claim 4, wherein the hydrophilic polymer is polyoxyethylene glycol, polyoxypropylene glycol, polyoxyethylene/propylene glycol, dextran, carboxymethyldextran, dextran sulfates, aminodextran, cellulose, carboxymethyl cellulose, chitin, chitosan, succinyl chitosan, carboxymethylchitin, carboxymethylchitosan, hyaluronic acid, a starch, an alginate, chondroitin sulfate, albumin, pullulan, carboxymethyl pullulan, polyglutamic acid, polylysine, polyaspartic acid, HPMA, styrene maleic anhydride copolymer, divinylethyl ether maleic anhydride copolymer, polyvinyl pyrrolidone, and polyvinylalcohol.

6. (Currently amended): A complex according to claim ~~[[5]]~~ 4, wherein the hydrophilic polymer is polyethylene glycol.

7. (Previously presented): A complex according to claim 6, wherein the polyethylene glycol has a molecular weight of about 1000-10000.

8. (Original): A complex according to claim 1, comprising a hydrophobic polymer, wherein the hydrophobic polymer is selected from a poly(alpha-hydroxy acid), polydioxanone, a polycarbonate, a polyanhydride, a polyorthoester, and a hydrophobic derivative of a poly(alpha-amino acid).

9. (Original): A complex according to claim 8, wherein the hydrophobic polymer is polylactic acid.

10. (Previously presented): A complex according to claim 1, wherein the bioactive agent is selected from the group consisting of topotecan, doxorubicin, adriamycin, vincristine, cisplatin, and a combination thereof.

11. (Currently amended): A complex according to claim 1, wherein the bioactive agent is topotecan hydrochloride.

12. (Currently amended): A method of treating a cancer comprising administering an effective amount of the complex according to claim ~~[[1]]~~ 10 to a patient in need thereof.

13. (Withdrawn): A method of treating osteo arthritis, rheumatoid arthritis, diabetic retinopathy, hemangiomas or psoriasis comprising administering an effective amount of the complex according to claim 1 to a patient in need thereof.

14. (Currently amended, Withdrawn): A complex ~~of an amphiphilic copolymer with~~ according to claim 1, wherein the water soluble cationic bioactive agent is a contrast agent; ~~wherein the amphiphilic copolymer has benzoyl-sulfonic acid groups on the hydrophobic segment of said copolymer.~~

15. (Withdrawn): A method of diagnostic imaging comprising administering an effective amount of the complex according to claim 14 to a patient in need thereof.

Claim 16. (Currently amended, Withdrawn): A process of making [[an]] the amphiphilic copolymer having benzoyl sulfonic acid groups according to claim 1, [[by]] said process comprising reacting [[the]] an amphiphilic copolymer with sulfobenzoic anhydride either in the melt or in solution.